A peptide inhibitor of TRPV6 (SOR-C13) completed a Phase I clinical safety trial 103 and has been shown to reduce growth in cell and animal models ovarian and prostate cancers 100, 101. This evidence concerns the gene TRPV6 and prostate carcinoma.